{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-040537","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.988126+00:00","generated_at":"2026-06-17T06:55:12.416015+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Annovis Bio reports Q4 2022 net loss of $7.7M; advances buntanetap trials","bullets":["Net loss Q4 2022 of $7.7M vs $5.9M in Q4 2021; full-year net loss $25.3M vs $14.5M.","Cash and equivalents $28.4M as of Dec 31, 2022; R&D spend $6.2M in Q4, up 114% YoY.","FDA authorized Phase 2/3 Alzheimer's trial; EU sites approved for Phase 3 Parkinson's trial.","Interim analysis for Phase 3 PD trial based on 132 patients; company proceeds as planned.","Appointed VP Process Chemistry and VP Toxicology; filed patent for neuropsychiatric uses."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-040537","json":"https://secwatch.observer/filing/0001104659-23-040537.json","markdown":"https://secwatch.observer/filing/0001104659-23-040537.md","text":"https://secwatch.observer/filing/0001104659-23-040537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465923040537/0001104659-23-040537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465923040537/tm2311180d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:55:12.416015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a382857988e7e0327b9fa4d76d6c707fe728484","claim":"Annovis Bio, Inc. reported the quarter and year ended December 31, 2022 results: net income net loss of $7.7 million, compared to a net loss of $5.9 million for the same period in 2021.","evidence_excerpt":"On April 3, 2023, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465923040537/0001104659-23-040537-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Net income","value":"net loss of $7.7 million, compared to a net loss of $5.9 million for the same period in 2021"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}